Tissue Handling and Repository

组织处理和储存库核心(核心B)的目标是提供服务，以优化 收集和分析匹配的临床数据和为研究项目、试点项目获得的生物标本 项目和临床组件。具体地说，核心将致力于提高临床数据的质量 收集，确定招募方案，通过共同的生物检疫处理提高效率， 并建立一个通用的、健康的对照样本库，为后续的功能研究召回。三 提出了具体的目标。首先，我们建议加强临床数据收集。基于Web的临床数据 收集仪器将为研究和临床试验开发、测试和分析。这个 CORE将与首席调查人员合作制定协议，以加强统一、完整和 站点之间的高质量数据收集。预计对于每个项目，快速开发时间和 调查人员控制将是可取的，适度规模的收藏将会积累起来。第二，我们建议 开发和应用生物样品跟踪和中央标本处理的工作流程方法。 将开发和应用工作流方法来划分、跟踪和连接生物标本收集 通过首席调查员、组织处理和储存库核心以及辅助(例如病理学、 流式细胞术)实验室。血清、DMA的处理和外周血的冷冻保存 将对患有1型糖尿病(T1 DM)、原发性干燥综合征的受试者进行单核细胞移植 (PSS)、炎症性肠病(IBD)和健康对照组。第三，我们建议制定一项 可重新绘制的健康对照和根据感兴趣的基因类型分层的患者资料库。增强了 提出了常用的健康对照和数据集，以便于招募和召回适当的人员 使用外周血白细胞进行机械性研究的性别、年龄和血统匹配的对照。

The goal of the Tissue Handling and Repository Core (Core B) is to provide services to optimize the collection and analysis of matched clinical data and biospecimens obtained for the Research Projects, Pilot Project and Clinical Components. Specifically, the Core will seek to enhance quality of clinical data collections, define recruitment protocols, improve efficiencies through common biospecimens processing, and develop a common, healthy control sample pool for recall for subsequent functional studies. Three specific aims are proposed. First, we propose to enhance clinical data collections. Web-based clinical data collection instruments will be developed, tested and analyzed for Research Studies and Clinical Trials. The Core will work with Principal Investigators to develop protocols which will enhance uniform, complete and high quality data collection between sites. It is anticipated that for each project, rapid development time and investigator-control will be desired, and that modest-sized collections will be accrued. Second, we propose to develop and apply a workflow methodology for biospecimen tracking and central specimen processing. Workflow methodology will be developed and applied to divide, track and link biospecimens collections through the Principal Investigator, the Tissue Handling and Repository Core, and Ancillary (e.g. Pathology, Flow cytometry) Laboratories. Processing of serum, DMA, and cryopreservation of peripheral blood mononuclear cells will be performed for subjects with Type 1 diabetes (T1DM), primary Sjogren's syndrome (pSS), inflammatory bowel disease (IBD), and healthy control subjects. Third, we propose to develop a redrawable healthy control and patient repository stratified on genotypes of interest. Enhancement of a common healthy control and dataset is proposed for the purposes of recruiting and recalling appropriate gender, age and ancestry-matched controls for mechanistic studies using peripheral blood leukocytes.